Not for human consumption
Not to be used on animals.
For lab research purposes only
The product is 99% pure
Crystalized visible powder or looks like an empty bottle: depends on available inventory

Tirzepatide is an antidiabetic medication used for the treatment of type 2 diabetes ^[10]^[13]^[14]^[15] and for weight loss.^[11]^[16] Tirzepatide is administered via subcutaneous injections (under the skin).^[10]^[13] It is sold under the brand names Mounjaro for diabetes treatment,^[10] and Zepbound for weight loss.^[11]

Clinical data
	Tirzepatide

Pronunciation	/tɜːrˈzɛpətaɪd/ tur-ZEP-ə-tyde
Trade names	Mounjaro, Zepbound
Other names	LY3298176, GIP/GLP-1 RA
AHFS/Drugs.com	Monograph
MedlinePlus	a622044
License data	US DailyMed: Tirzepatide
Pregnancy category	AU: D^[1]
Routes of administration	Subcutaneous
Drug class	Antidiabetic, GLP-1 receptor agonist
ATC code	A10BX16 (WHO) QA10BX16 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)^[1]^[2]^[3]^[4] CA: ℞-only ^[5]^[6]^[7] UK: POM (Prescription only)^[8]^[9] US: ℞-only ^[10]^[11] EU: Rx-only^[12]
Pharmacokinetic data
Bioavailability	80%
Protein binding	Albumin
Metabolism	Proteolytic cleavage, β-oxidation of fatty diacid section and amide hydrolysis
Elimination half-life	5 days
Excretion	Urine and faeces
Identifiers
show IUPAC name
CAS Number	2023788-19-2
PubChem CID	156588324
IUPHAR/BPS	11429
DrugBank	DB15171
ChemSpider	76714503
UNII	OYN3CCI6QE
KEGG	D11360
ChEBI	CHEBI:194186
ChEMBL	ChEMBL4297839
Chemical and physical data
Formula	C₂₂₅H₃₄₈N₄₈O₆₈
Molar mass	4813.527 g·mol⁻¹
3D model (JSmol)	Interactive image
show SMILES
show InChI

Tirzepatide was approved for treatment of diabetes in the United States in May 2022,^[10]^[13] in the European Union in September 2022,^[12] in Canada in November 2022,^[18] and in Australia in December 2022.^[2] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[19]^[20] It was approved by the FDA for weight loss in November 2023.^[16]^[21] In November 2023, the UK Medicines and Healthcare products Regulatory Agency revised the indication for tirzepatide to include treatment for weight loss.^[8]^[22]